Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary c...
For the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.
Montefiore Medical Center, Bronx, New York, United States
University of Alabama at Birmingham, Birmingham, Alabama, United States
University of California San Francisco (Data collection only), San Francisco, California, United States
University of Chicago Medical Center, Chicago, Illinois, United States
KK Women's and Children's Hospital, Singapore, Singapore
Barnes-Jewish Hospital, Saint Louis, Missouri, United States
Calcutta National Medical College and Hospital, Kolkata, West Bengal, India
Amsterdam UMC, location VUmc, Amsterdam, Noord-Holland, Netherlands
Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
West Middlesex University Hospital, Isleworth, United Kingdom
Chelsea and Westminster Hospital, London, United Kingdom
Women's Hospital of Zhejiang Medical University, Hangzhou, Zhejiang, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.